Bansisons Tea Industries Ltd (519353)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 2 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 23 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Bansisons Tea Industries Ltd reported Q2 FY27 results on 2 Nov 2026: revenue ₹4.2 Cr, and net profit ₹-0.0 Cr (against a profit a year earlier); the operating margin was -1.6%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹4.2 | — | +145.1% |
| செயல்பாட்டு லாபம் | ₹-0.1 | — | நஷ்டம் அதிகரித்தது |
| நிகர லாபம் | ₹-0.0 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| EPS (₹) | -0.05 | நஷ்டமாக | நஷ்டம் அதிகரித்தது |
| செயல்பாட்டு லாப வரம்பு | -1.6% | — | — |
- நஷ்டத்தில்: ஓராண்டுக்கு முன் லாபம்
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Novyra Pharmachem reported standalone revenue from operations of Rs 426.78 lakh for Q2 FY27 (quarter ended Sep 30, 2026), up from Rs 172.61 lakh in Q1 FY27 and Rs 3.31 lakh in Q2 FY26. Despite top-line expansion driven primarily by its Pharma segment (Rs 423.08 lakh), the company incurred a net loss of Rs 3.32 lakh compared to a profit of Rs 0.10 lakh in Q2 FY26. For H1 FY27, total revenue stood at Rs 599.39 lakh with a net loss of Rs 5.31 lakh. Basic and diluted EPS for the quarter was Rs -0.05.
- Total revenue from operations reached Rs 426.78 lakh in Q2 FY27 versus Rs 3.31 lakh in Q2 FY26
- Net loss for the quarter came in at Rs 3.32 lakh compared to net profit of Rs 0.10 lakh in Q2 FY26
- Pharma segment contributed Rs 423.08 lakh to quarterly revenue, generating segment profit of Rs 3.20 lakh
- H1 FY27 revenue reached Rs 599.39 lakh with a cumulative net loss of Rs 5.31 lakh
- Basic and diluted EPS stood at Rs -0.05 for Q2 FY27
Novyra Pharmachem Ltd has scheduled a meeting of its Board of Directors on Monday, November 2, 2026. The board will consider and approve the unaudited financial results for the second quarter ended September 30, 2026, alongside the Auditor's Limited Review Report. The micro-cap company (market cap Rs 6 Cr) reported revenue of Rs 1.73 Cr and a net loss of Rs 0.02 Cr in Q1 FY27 (June 2026). This is a routine administrative intimation under SEBI Listing Regulations.
- Board meeting scheduled for Monday, November 2, 2026
- To review and approve unaudited financial results for Q2 ended September 30, 2026
- Auditor's Limited Review Report to be considered during the meeting
- Meeting convened pursuant to Regulation 29 of SEBI LODR Regulations, 2015
Bansisons Tea Industries Limited has officially received approval to change its corporate name to 'Novyra Pharmachem Limited' effective from January 19, 2026. The name change signals a business pivot from tea into pharmaceuticals, life sciences, API manufacturing, specialty chemicals, and CRO/CDMO services. The company is a micro-cap with a market capitalization of Rs 7 Cr, which reported FY26 revenue of Rs 0.1 Cr and a net loss of Rs -5.37 Cr. Investors should note that while the corporate identity has shifted, no concrete capital outlay, plant locations, or execution timelines were quantified in this filing.
- Corporate name changed from 'Bansisons Tea Industries Limited' to 'Novyra Pharmachem Limited'
- Approval received on 22 August 2026 pursuant to an application dated 16 July 2026
- Certificate of Incorporation issued by the RoC Central Processing Centre on 19 January 2026
- Pivoting operations into active pharmaceutical ingredients (APIs), bulk drugs, and CDMO/CRO services
Novyra Pharmachem (formerly Bansisons Tea Industries) reported standalone revenue from operations of ₹1.73 Cr (₹172.61 lakhs) for the quarter ended June 30, 2026, compared to ₹0.10 Cr in the preceding quarter and ₹0.03 Cr in Q1 FY26. Net loss narrowed substantially to ₹0.02 Cr (₹1.99 lakhs) from a loss of ₹5.34 Cr in Q4 FY26. Total revenue was entirely generated from the Pharma segment, while the legacy Tea Estate and Real Estate segments reported zero revenue. Basic and diluted EPS for the quarter stood at ₹(0.03).
- Revenue from operations rose to ₹1.73 Cr (₹172.61 lakhs) in Q1 FY27 from ₹0.10 Cr in Q4 FY26
- Net loss narrowed significantly to ₹0.02 Cr (₹1.99 lakhs) from ₹5.34 Cr in the preceding quarter
- Pharma segment contributed 100% of the operational revenue at ₹172.61 lakhs
- Quarterly EPS improved to ₹(0.03) compared to ₹(8.43) in Q4 FY26
Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of only ₹7 Cr and reported a significant net loss of ₹5.34 Cr in the March 2026 quarter. With TTM revenue at nearly zero and a net worth of just ₹1 Cr, the company's financial position is precarious. The name change suggests a potential shift from tea to the pharmaceutical/chemical sector, which investors should monitor for operational updates.
- Board meeting scheduled for August 14, 2026, to consider Q1 results.
- Company reported a net loss of ₹5.34 Cr in the previous quarter (March 2026).
- Market capitalization stands at a minimal ₹7 Cr with a net worth of ₹1 Cr.
- TTM revenue is effectively ₹0 Cr, indicating a lack of core operations in the recent past.
Bansisons Tea Industries Ltd has updated its official website to www.novyrapharmachemltd.com following its name change to Novyra Pharmachem Limited. This is a procedural update to comply with SEBI (LODR) Regulations. The company remains a micro-cap entity with a market capitalization of Rs 7 Cr and reported zero revenue for the TTM period. Investors should note the significant financial distress, with a TTM PAT of Rs -5 Cr and an operating margin of -5380%.
- Official website address changed from www.bansisonstea.com to www.novyrapharmachemltd.com
- Company name changed to Novyra Pharmachem Limited from Bansisons Tea Industries Ltd
- TTM Revenue stands at Rs 0 Cr as of the latest financial context
- TTM PAT is significantly negative at Rs -5 Cr
- Promoter holding remains stable at 23.15% as of March 2026
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
